PAHC
HoldUnloved QualityAI neutralPhibro Animal Health Corporation · Healthcare · United States · $1.6B cap · $9.1M/day traded
$39.03 +0.6% · close 26 Oct · scored 27 Oct
Unloved Quality: Strong and cheap; the market has not turned yet.
As of 27 Oct 2026, MoatMap's StockRank for Phibro Animal Health Corporation (PAHC) is 63/100, ranked against 24,000+ stocks in 35 markets (Quality 63, Value 50, Momentum 45, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Phibro Animal Health sells medicated feed additives, vaccines and nutritional products to poultry, pork and cattle producers. It reported record fiscal-year sales, and forward earnings estimates have risen 16% in the past month, largely helped by its acquisition of Zoetis's medicated feed additive portfolio. The earnings momentum is real, but the company carries meaningful debt from that deal, operates in a lower-margin corner of animal health, and sells to livestock producers whose margins are squeezed by rising grain costs.
ABOUT PHIBRO ANIMAL HEALTH CORPORATION
Read
Phibro Animal Health Corporation is a U.S.-based company developing, manufacturing, and marketing a diverse portfolio of animal health and nutrition products, including medicated feed additives, vaccines, and nutritional supplements. The company's competitive moat is built on its extensive industry experience, strong relationships with livestock producers, and a broad product offering vital for animal productivity and disease prevention. This integrated approach solidifies its position in the global animal health market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 942.3M | 977.9M | 1.0B | 1.3B | 11.2% | 1.5B | 1.3B | 1.4B | 2.4% |
| EPS | 1.21 | 0.81 | 0.06 | 1.19 | -0.6% | 2.43 | 1.29 | 1.42 | 6.1% |
| Shares | 40.5M | 40.5M | 40.5M | 40.5M | +0.1% | — | — | — | — |
| Debt | 470.5M | 510.0M | 525.5M | 761.6M | 17.4% | 795.6M | — | — | — |
| Equity | 262.4M | 282.5M | 256.6M | 285.7M | 2.9% | — | — | — | — |
| Op CF | 31.6M | 13.3M | 87.6M | 80.1M | 36.3% | 69.0M | — | — | — |
| Inv CF | -22.6M | -74.0M | -48.2M | -288.7M | — | — | — | — | — |
| Fin CF | 16.3M | 27.0M | -6.8M | 207.1M | — | — | — | — | — |
39% above its 52-week low and back above a rising 50-day average since 2 Oct 2026.
The Momentum score still reads 45: it weighs six months of price and earnings revisions, so it trails a turn like this.
Swung more than 68% of stocks we rank over the past year (54% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PAHC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PAHC | Phibro Animal Health Corporation(you) | $1.6B | 63 | Hold |
| ETON | Eton Pharmaceuticals, Inc. | $1.4B | 59 | Hold |
| XERS | Xeris Biopharma Holdings, Inc. | $1.9B | 55 | Hold |
| PBH | Prestige Consumer Healthcare Inc. | $2.3B | 68 | Buy |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.0B | 74 | Buy |
| TRLV | Trulieve Cannabis Corp. | $2.0B | 80 | Buy |
| ANIP | ANI Pharmaceuticals, Inc. | $1.7B | 89 | Strong Buy |
| PCRX | Pacira BioSciences, Inc. | $1.5B | 90 | Strong Buy |
| GTII.CN | Green Thumb Industries Inc. | $1.4B | 89 | Strong Buy |
| COLL | Collegium Pharmaceutical, Inc. | $747M | 82 | Strong Buy |
Peer medians: ROE -30.5% · P/E 27.3x · Gross margin 63.4%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.